Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Fisher, Anna Brown, N. Dimitrov, R. Poisson, C. Redmond, R. Margolese, D. Bowman, N. Wolmark, D. Wickerham, C. Kardinal (1990)Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 9
R. Dent, M. Trudeau, K. Pritchard, W. Hanna, H. Kahn, C. Sawka, L. Lickley, E. Rawlinson, P. Sun, S. Narod (2007)Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Clinical Cancer Research, 13
S. Rodríguez-Pinilla, D. Sarrió, E. Honrado, G. Moreno-Bueno, D. Hardisson, F. Calero, J. Benítez, J. Palacios (2006)Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas
Journal of Clinical Pathology, 60
T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. Eisen, M. Rijn, S. Jeffrey, T. Thorsen, H. Quist, J. Matese, P. Brown, D. Botstein, P. Lønning, A. Børresen-Dale (2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Proceedings of the National Academy of Sciences of the United States of America, 98
R Tibshirani T Sørlie (2003)Repeated observation of breast tumor subtypes in independent gene expression data sets
Proc Natl Acad Sci U S A, 100
L. Harris, G. Broadwater, N. Lin, A. Miron, S. Schnitt, D. Cowan, J. Lara, I. Bleiweiss, D. Berry, M. Ellis, D. Hayes, E. Winer, L. Dressler (2006)Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
Breast Cancer Research, 8
Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome
T. Sørlie, R. Tibshirani, Joel Parker, T. Hastie, J. Marron, A. Nobel, Shibing Deng, H. Johnsen, Robert Pesich, S. Geisler, J. Demeter, C. Perou, P. Lønning, P. Brown, A. Børresen-Dale, D. Botstein (2003)Repeated observation of breast tumor subtypes in independent gene expression data sets
Proceedings of the National Academy of Sciences of the United States of America, 100
S. Nofech-Mozes, M. Trudeau, H. Kahn, R. Dent, E. Rawlinson, P. Sun, S. Narod, W. Hanna (2009)Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers
Breast Cancer Research and Treatment, 118
M. Cheang, D. Voduc, C. Bajdik, S. Leung, S. McKinney, S. Chia, C. Perou, T. Nielsen (2008)Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
Clinical Cancer Research, 14
F. Heitz, P. Harter, A. Traut, H. Lueck, B. Beutel, A. Bois (2008)Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors
Journal of Clinical Oncology, 26
W. Foulkes, J. Brunet, I. Stefansson, O. Straume, P. Chappuis, L. Bégin, N. Hamel, J. Goffin, N. Wong, M. Trudel, L. Kapusta, P. Porter, L. Akslen (2004)The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer
Cancer Research, 64
M. Tischkowitz, J. Brunet, L. Bégin, D. Huntsman, M. Cheang, L. Akslen, T. Nielsen, W. Foulkes (2007)Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
BMC Cancer, 7
CM Perou M Rijn (2002)Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome
Am J Pathol, 161
V. Patil, R. Singhai, Amit Patil, P. Gurav (2011)Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.
Breast cancer, 3
N. Lin, E. Claus, J. Sohl, A. Razzak, A. Arnaout, E. Winer (2008)Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer
S. Dawood, K. Broglio, F. Esteva, W. Yang, S. Kau, R. Islam, Constance Albarracin, Tse Yu, Marjorie Green, G. Hortobagyi, A. González-Angulo (2009)Survival among women with triple receptor-negative breast cancer and brain metastases.
Annals of oncology : official journal of the European Society for Medical Oncology, 20 4
CM Perou T Sørlie (2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Proc Natl Acad Sci USA, 98
Jason Herschkowitz, K. Simin, V. Weigman, I. Mikaelian, Jerry Usary, Zhiyuan Hu, Karen Rasmussen, L. Jones, S. Assefnia, S. Chandrasekharan, M. Backlund, Yuzhi Yin, A. Khramtsov, Roy Bastein, J. Quackenbush, R. Glazer, P. Brown, Jeffrey Green, L. Kopelovich, P. Furth, J. Palazzo, O. Olopade, P. Bernard, G. Churchill, T. Dyke, C. Perou (2007)Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
Genome Biology, 8
F. Bertucci, P. Finetti, N. Cervera, B. Esterni, F. Hermitte, P. Viens, D. Birnbaum (2008)How basal are triple‐negative breast cancers?
International Journal of Cancer, 123
R Singhai VW Patil (2011)Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
Breast Canc Targ Ther, 3
S. Krishnamurthy (2007)Morphological and Immunophenotypic Analysis of Breast Carcinomas With Basal and Myoepithelial Differentiation
Breast Diseases: A Year Book Quarterly, 17
A. Prat, C. Perou (2009)Mammary development meets cancer genomics
Nature Medicine, 15
C. Perou, T. Sørlie, M. Eisen, M. Rijn, S. Jeffrey, Christian Rees, J. Pollack, D. Ross, H. Johnsen, L. Akslen, Ø. Fluge, Alexander Pergamenschikov, Cheryl Williams, Shirley Zhu, P. Lønning, A. Børresen-Dale, P. Brown, D. Botstein (2000)Molecular portraits of human breast tumours
TC Putti EA Rakha (2006)Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation
J Pathol, 208
H. Roché, P. Fumoleau, M. Spielmann, J. Canon, T. Delozier, D. Serin, M. Symann, P. Kerbrat, P. Soulié, F. Eichler, P. Viens, A. Monnier, A. Vindevoghel, M. Campone, M. Goudier, J. Bonneterre, J. Ferrero, Anne-Laure Martin, J. Genève, B. Asselain (2006)Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 36
M. Prabu, V. Raina, N. Shukla, B. Mohanti, S. Deo (2011)A study of triple-negative breast cancer at a cancer institute in India.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
Xueri Li (2009)Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients:The FNCLCC PACS 01 Trial
Journal of Evidence-based Medicine
Abstract Triple negative breast cancer (TNBC) constitutes 10–25% of patients with breast cancer. TNBC is an aggressive phenotype affecting younger age groups and has poor prognosis. We retrospectively analysed 50 triple negative breast cancer patients attending our outpatient department among 270 breast cancer patients. The incidence of TNBC was 18.5%, and most of them were premenopausal 56% (28/50) with mean age was 46.66 ± 13.87 (Range 28–72 years). Most of them had Invasive ductal cancer 94% (47/50) and were high grade (Grade 3−96%)(48/50). Five patients presented with metastatic disease (2 patients only Skeletal, 1 patient with Skeletal and Lung, 1 patient with Lung and 1 patient with Liver) and 7 patients developed recurrence (all 7 had chest wall recurrence, 3 had supraclavicular lymph node recurrence, 2 had skeletal metastases and 1 had developed brain metastases) during follow up. The mean disease free survival was 15 months (Range 3–58 months) and overall survival was 20.14 months (Range 5–70 months). Fifty six percent (28/50) of patients were premenopausal and mean age of presentation was 46.66 ± 13.87 years (Range 28–72 years). Ten percent (5/50) presented with metastatic disease and 15% (7/45) developed metastases during follow up. Five patients (10%) died during follow up. Hence, Triple negative breast cancer is aggressive, with rapid progression leading to mortality in younger patients.
Indian Journal of Surgical Oncology – Springer Journals
Published: Mar 1, 2012
Keywords: surgical oncology; oncology; surgery
Access the full text.
Sign up today, get DeepDyve free for 14 days.